Log in to save to my catalogue

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positi...

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_97cb292e26054c75a968bad21fc37c9b

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

About this item

Full title

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Publisher

London: Nature Publishing Group UK

Journal title

NPJ breast cancer, 2021-04, Vol.7 (1), p.44-44, Article 44

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic
PTEN
mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed. This Phase I multipart expansion study assessed oral capivasertib with fulvestrant in patients wit...

Alternative Titles

Full title

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_97cb292e26054c75a968bad21fc37c9b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_97cb292e26054c75a968bad21fc37c9b

Other Identifiers

ISSN

2374-4677

E-ISSN

2374-4677

DOI

10.1038/s41523-021-00251-7

How to access this item